Novo Nordisk A/S (NOV)
XDUS
Real-time Data
06:00 AM
Day's Range
39.5652 wk Range
30.26Overview - NOV - Novo Nordisk A/S
Key Statistics
Valuation
Enterprise Value
104.49B
P/E (Trailing)
‪1.73‬
PEG Ratio
‪-0.08‬
Price / Book
‪0.80‬
EV / EBITDA
‪0.69‬
Profitability
Gross Margin
‪78.21%‬
Profit Margin
‪80.97%‬
Operating Margin
‪43.59%‬
Return on Assets
‪18.86%‬
Return on Equity
‪52.78%‬
Ownership
Shares Outstanding
4.42B
Price stats
50-Day Avg
‪41.49‬
200-Day Avg
‪39.87‬
Dividends
Frequency
Semi-Annual
Shariah Compliance
Report Date: Feb 20, 2025
Screened by Zoya using the AAOIFI methodology.
Peers - NOV - Novo Nordisk A/S
Peer Comparison
Compared with companies in Drug Manufacturers - General listed on XDUS.
- NOVXDUSNovo Nordisk A/S-21.31%52-week change1.72P/E (Trailing)‪80.97%‬Profit Margin
- LLYXDUSEli Lilly and Company+44.43%52-week change46.77P/E (Trailing)‪83.04%‬Profit Margin
- BAYAXDUSBayer AG Sponsored ADR+42.31%52-week change-12.72P/E (Trailing)‪58.75%‬Profit Margin
- 6MKXDUSMerck & Co., Inc.+41.66%52-week change17.34P/E (Trailing)‪74.80%‬Profit Margin
- IDPXDUSBiogen Inc.+35.99%52-week change21.13P/E (Trailing)‪75.69%‬Profit Margin
- JNJXDUSJohnson & Johnson+33.91%52-week change20.83P/E (Trailing)‪67.87%‬Profit Margin
- JNJ0XDUSJohnson & Johnson CDR+32.38%52-week change19.41P/E (Trailing)‪67.87%‬Profit Margin
Profile Summary - NOV - Novo Nordisk A/S
About
Novo Nordisk A/S is a global pharmaceutical company specializing in research, development, and manufacturing of treatments for serious chronic diseases. Founded through the 1989 merger of Danish insulin pioneers Nordisk Insulaboratorium and Novo Terapeutisk Laboratorium, it traces its roots to 1923 when commercial…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
